Equities
Health CareMedical Equipment and Services
  • Price (USD)162.37
  • Today's Change1.05 / 0.65%
  • Shares traded50.78k
  • 1 Year change+20.88%
  • Beta0.8891
Data delayed at least 15 minutes, as of Nov 21 2024 15:21 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company provides diagnostic insights from the results of its laboratory testing to enable people, physicians, and organizations to take action to improve health outcomes. It operates through the DIS segment, which provides diagnostic information services to a range of customers within its primary customer channels: physicians, hospitals, and patients and consumers. It offers broad access to clinical testing through a nationwide network of laboratories, patient service centers, phlebotomists in physician offices, and connectivity resources, including call centers and mobile phlebotomists, nurses and other health and wellness professionals. The Company also focuses on artificial intelligence (AI) and digital pathology solutions for biopharmaceutical companies and pathology laboratories. It has implemented AI, digital and automation technologies across several laboratory and business functions.

  • Revenue in USD (TTM)9.54bn
  • Net income in USD838.00m
  • Incorporated1996
  • Employees40.00k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
DGX:NYQ since
announced
Transaction
value
University Hospitals Health System-Outreach Laboratory Services BusinessAnnounced21 Aug 202421 Aug 2024Announced7.59%--
Lifelabs IncDeal completed03 Jul 202403 Jul 2024Deal completed18.83%987.13m
Allina Health Systems Inc-Select Laboratory AssetsDeal completed26 Jun 202426 Jun 2024Deal completed17.40%--
PathAI Inc-Select AssetsDeal completed01 May 202401 May 2024Deal completed17.51%--
Lenco Diagnostic Laboratories IncDeal completed01 Feb 202401 Feb 2024Deal completed26.43%111.00m
Data delayed at least 15 minutes, as of Nov 21 2024 15:21 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Encompass Health Corp5.22bn431.20m9.97bn22.36k23.415.0911.661.914.234.1151.1019.450.8396--9.38233,270.709.076.3711.877.9495.4995.5810.809.16--6.140.48630.7810.412.3441.314.4916.60-10.42
Universal Health Services, Inc.15.42bn1.03bn13.04bn73.35k13.141.978.010.84615.0315.03225.85100.141.09--6.93210,194.407.416.448.687.63----6.786.551.287.700.41056.066.595.806.32-1.471.1714.87
Davita Inc12.67bn827.68m13.23bn70.00k17.4034.487.051.049.289.28141.504.680.735771.345.90180,951.606.585.628.887.4532.8030.708.948.331.334.770.8115--4.571.2626.442.33-10.47--
Tenet Healthcare Corp20.97bn3.13bn14.44bn78.14k4.863.773.020.688531.2631.26209.8140.320.73649.497.15268,376.3013.863.6120.235.0982.6182.9718.834.951.525.370.61450.007.172.3349.0241.424.01--
Molina Healthcare Inc39.20bn1.14bn16.85bn18.00k14.953.5212.720.429919.7019.70674.9783.682.56--13.712,177,722.007.477.6216.5816.8016.1215.992.923.04--14.830.34650.006.5612.5237.759.0622.87--
Quest Diagnostics Inc9.54bn838.00m18.01bn40.00k21.662.6513.491.897.457.4584.7960.790.64534.777.18238,475.005.879.286.7710.8132.9436.649.1012.971.178.870.474625.07-6.384.20-9.773.401.277.43
Labcorp Holdings Inc12.71bn435.50m19.89bn67.00k46.092.4418.841.565.165.16150.4097.610.716219.415.93189,743.302.466.273.007.3727.9232.333.449.511.305.590.455--2.511.42-62.16-16.403.62--
Natera Inc1.53bn-214.69m20.76bn3.28k--23.72--13.55-1.77-1.7712.597.081.0114.295.45466,774.80-14.14-36.17-17.55-46.6057.6645.88-14.01-56.154.23--0.2947--31.9933.2620.63--58.81--
Data as of Nov 21 2024. Currency figures normalised to Quest Diagnostics Inc's reporting currency: US Dollar USD

Institutional shareholders

39.27%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Sep 202413.46m12.06%
BlackRock Fund Advisorsas of 30 Sep 20246.43m5.76%
SSgA Funds Management, Inc.as of 30 Sep 20245.26m4.72%
T. Rowe Price Associates, Inc. (IM)as of 30 Sep 20243.69m3.31%
Victory Capital Management, Inc. (Investment Management)as of 30 Sep 20243.46m3.10%
Geode Capital Management LLCas of 30 Sep 20242.62m2.34%
Davis Selected Advisers LPas of 30 Sep 20242.40m2.15%
American Century Investment Management, Inc.as of 30 Sep 20242.29m2.05%
Grantham, Mayo, Van Otterloo & Co. LLCas of 30 Sep 20242.24m2.01%
Wellington Management Co. LLPas of 30 Sep 20241.98m1.77%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.